Strongbridge Biopharma plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Strongbridge Biopharma plc operates as a commercial-stage biopharmaceutical company focused on the development, in-licensing, acquisition, and commercialization of therapies targeting rare diseases with significant unmet needs, particularly in endocrinology and neuromuscular disorders; its core products and services include KEVEYIS (dichlorphenamide), an FDA-approved oral carbonic anhydrase inhibitor for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States, alongside clinical-stage candidates such as RECORLEV (levoketoconazole), a cortisol synthesis inhibitor in Phase III trials for endogenous Cushing's syndrome, and veldoreotide, a somatostatin analog that has completed Phase II trials for acromegaly. Founded in 1996 and headquartered in Trevose, Pennsylvania, the company conducts global operations with distribution capabilities spanning multiple regions. In a major strategic development, Strongbridge Biopharma was acquired by Xeris Pharmaceuticals, Inc. in October 2021 through a stock and contingent value rights transaction, resulting in the combination of operations under Xeris Biopharma Holdings, Inc., which realized approximately $50 million in pre-tax synergies by the end of 2022 from cost savings in general administration, commercial functions, and medical affairs, while expanding the pipeline in rare endocrine diseases.
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing's Syndrome
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Strongbridge Biopharma plc - SBBP
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBP
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBP
SHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plc